Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

Bibliographic Details
Main Authors:	Nauck, Michael, Weinstock, Ruth S., Umpierrez, Guillermo E., Guerci, Bruno, Skrivanek, Zachary, Milicevic, Zvonko
Format:	Online
Language:	English
Published:	American Diabetes Association 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113177/

Similar Items

Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study
by: Weinstock, R. S., et al.
Published: (2015)

Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once‐weekly dulaglutide AWARD programme
by: Dungan, K. M., et al.
Published: (2016)

A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD‐8)
by: Dungan, K. M., et al.
Published: (2016)

Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once‐weekly dulaglutide treatment
by: Umpierrez, G. E., et al.
Published: (2016)

Similar efficacy and safety of once‐weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years
by: Boustani, M. A., et al.
Published: (2016)

Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes
by: Kashiwagi, Atsunori, et al.
Published: (2011)

Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks
by: Kadowaki, Takashi, et al.
Published: (2012)

Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes: A randomized, open-label trial
by: Pratley, Richard E., et al.
Published: (2012)

Mode of administration of dulaglutide: implications for treatment adherence
by: Amblee, Ambika
Published: (2016)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
by: Thompson, Angela M, et al.
Published: (2016)

Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
by: Ferdinand, Keith C., et al.
Published: (2016)

52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B
by: Piratvisuth, Teerha, et al.
Published: (2013)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
by: Onishi, Yukiko, et al.
Published: (2012)

A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine
by: Mathieu, Chantal, et al.
Published: (2015)

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
by: Wysham, C, et al.
Published: (2011)

Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review
by: Zhang, Lin, et al.
Published: (2016)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
by: Gurung, Tara, et al.
Published: (2015)

The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes
by: Inagaki, Nobuya, et al.
Published: (2016)

Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes
by: Edwards, Krystal L, et al.
Published: (2015)

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study
by: Odawara, M., et al.
Published: (2016)

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study
by: Russell-Jones, David, et al.
Published: (2012)

Safety recommendation A-06-52
Published: (2007)

Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes: A pilot, randomized, controlled study
by: Umpierrez, Guillermo E., et al.
Published: (2013)

Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks
by: Diamant, Michaela, et al.
Published: (2012)

Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open‐label, phase III, non‐inferiority study
by: Araki, E., et al.
Published: (2015)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
by: De Benedetti, F, et al.
Published: (2011)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
by: De Benedetti, Fabrizio, et al.
Published: (2012)

Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma
by: Raphael, Gordon, et al.
Published: (2016)

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
by: Forst, T, et al.
Published: (2014)

The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study
by: Yataba, Ikuko, et al.
Published: (2016)

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study
by: Miyagawa, J., et al.
Published: (2015)

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial
by: Schernthaner, Guntram, et al.
Published: (2013)

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515
by: Schernthaner, G, et al.
Published: (2013)

Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial
by: Kondo, Yaeko, et al.
Published: (2016)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
by: Sharma, Ashish Kumar, et al.
Published: (2012)

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
by: Nauck, Michael A., et al.
Published: (2011)

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
by: Arjona Ferreira, Juan Camilo, et al.
Published: (2013)

Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial)
by: Bergenstal, Richard M., et al.
Published: (2012)

Efficacy and Safety of Sitagliptin for the Treatment of New-Onset Diabetes after Renal Transplantation
by: Boerner, Brian P., et al.
Published: (2014)

Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury
by: Asakawa, Masahiro, et al.
Published: (2015)